Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Infective Agents

Docetaxel

Cyclophosphamide

Epirubicin

Taxane

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Tubulin Modulators

Antimitotic Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks

intravenous infusion on day one every three weeks

4 cycles, intravenous use, day 1 every three weeks

4 cycles, intravenous infusion, day 1 every three weeks

4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy

6 cycles, intravenous infusion, day 1 every 3 weeks

6 cycles, intravenous infusion, day one every three weeks

Ulrike A. Nitz, Prof. Dr. med.

Nadia Harbeck, Prof. Dr. med.

The planned trial compares an anthracycline-free taxane based regimen versus a modern third generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors. The aim is to define a further anthracycline-free standard and to spare anthracycline toxicity to a patient, who will only have a modest benefit from this compound. Prior to randomization for chemotherapy for all patients with HR positive disease OncotypeDX® will be performed to identify patients who should not receive chemotherapy.

Secondary objectives of this trial will be to compare overall survival and toxicity between the two chemotherapy arms, to evaluate survival in the observation arm and to perform translational research regarding prognostic and predictive factors.

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	NCT01049425	Primary Breast ... Her2 Non-overex...	Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel	18 Years - 75 Years	West German Study Group
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	NCT01049425	Primary Breast ... Her2 Non-overex...	Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel	18 Years - 75 Years	West German Study Group
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	NCT01049425	Primary Breast ... Her2 Non-overex...	Epirubicin Cyclophosphamid... Docetaxel Cyclophosphamid... Docetaxel	18 Years - 75 Years	West German Study Group

Spots Global Cancer Trial Database for oncotypdx

Every month we try and update this database with for oncotypdx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for oncotypdx

Every month we try and update this database with for oncotypdx cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for oncotypdx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.